Interstitial Lung Disease (ILD): In the PHAROS trial, 1 patient (1%) receiving MEKTOVI with BRAFTOVI developed pneumonitis. Assess new or progressive unexplained pulmonary symptoms or findings for ...

It’s the biggest battlefield innovation in a generation.” Last July, U.S. Secretary of Defense Pete Hegseth acknowledged an ...

Maker Former CEO Ron Johnson Imagined Sales in J.C. Penney's home goods department are down 30 percent this year, and ...

Dreamforce 2025 is officially a wrap! It was a packed few days - we kicked off with the traditional opening keynote from ...